MSInsight, a French healthtech company, is empowering the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown as an indicator of treatment response, especially for immune checkpoint inhibitors and as an important pan-cancer biomarker. We aim at proposing bioinformatic tools for delivering insights on microsatellite mutational variations, using Next-Generation Sequencing data. Our flagship product, MSIcare, will be available as a robust diagnostic, pronostic, theranostic assistant for guiding clinical decision-making.